THE PEER-REVIEWED FORUM FOR EVIDENCE IN BENEFIT DESIGN ™ SEPTEMBER 2011
VOLUME 4, NUMBER 5
FOR PAYERS, PURCHASERS, POLICYMAKERS, AND OTHER HEALTHCARE STAKEHOLDERS
Theme Issue
CARDIOMETABOLIC HEALTH AND WELLNESS Introduction: In Search of Stakeholder Collaboration to Stem the Cardiometabolic Epidemic Obesity in the Workplace: Impact on Cardiovascular Disease, Cost, and Utilization of Care ™
Alberto M. Colombi, MD, MPH; G. Craig Wood, MS
Stakeholder Perspective by Wayne M. Lednar, MD, PhD
A Call to Action: Responding to the Future Forecasting of Cardiovascular Disease in America Robert Lee Page II, PharmD, MSPH, FAHA, FCCP, FASCP, FASHP, BCPS (AQ cards); Vahram Ghushchyan, PhD; Kavita Nair, PhD
Stakeholder Perspective by James T. Kenney, RPh, MBA
Atypical Antipsychotics and Metabolic Syndrome in Patients with Schizophrenia: Risk Factors, Monitoring, and Healthcare Implications Henry J. Riordan, PhD; Paola Antonini, MD, PhD; Michael F. Murphy, MD, PhD
Stakeholder Perspective by Atheer A. Kaddis, PharmD
Current Therapies and Emerging Drugs in the Pipeline for Type 2 Diabetes Quang T. Nguyen, DO; Karmella T. Thomas, BS, RD; Katie B. Lyons, MS II; Loida D. Nguyen, PharmD, BCBS; Raymond A. Plodkowski, MD
Stakeholder Perspective by James V. Felicetta, MD
Lipid Management in Patients with Type 2 Diabetes Marsha J. Daniel, PharmD, cPh, CDE
Stakeholder Perspective by Gary M. Owens, MD
©2011 Engage Healthcare Communications, LLC www.AHDBonline.com